HYDERABAD, India – August 21st, 2017 – At the 24th Congress & General Assembly of the International Union of Crystallography (IUCr), Bruker today announces the new, high-performance D8 VENTURE BIOTOOLSTM for laboratory macromolecular crystallography.
The D8 VENTURE BIOTOOLS feature major advances in source, detector and sample handling technology:
Dr. Vernon Smith, the Business Development Manager for Macromolecular Crystallography at Bruker AXS, noted: “With the D8 VENTURE BIOTOOLS, Bruker has once again set new standards in crystallography systems for the home laboratory. Our extremely bright and stable IµS DIAMOND X-ray source and our large area PHOTON III photon counting detector enable highly accurate data to be collected very quickly. By combining this unprecedented performance with fast, reliable handling automation, the new D8 VENTURE BIOTOOLS provide researchers the opportunity to move from crystal to structure more efficiently than ever before.”
Professor Elena Conti, Director at the Max-Planck-Institute for Biochemistry in Martinsried, Germany, stated: “The D8 VENTURE with METALJETTM has enabled my group to collect quality data from even our most difficult projects and has made our synchrotron trips more productive. With the addition of the new SCOUT sample changer, we expect this productivity to increase even further by being able to identify crystals suitable for structure determination more effectively. Taking less time to determine individual protein structures will enable us to push forward in our overall research goals more quickly.”
For more than 55 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nanoanalysis and industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research, clinical microbiology and molecular pathology research.
Investor Contact:
T: +1 (978) 663-3660 x1479
E: investor.relations@bruker.com
Media Contact:
Dr. Heiko Ress
Bruker AXS Director Marketing Communications
T: +49 721 50997-0
E: heiko.ress@bruker.com